Fed-Fasted, Single and Multiple Ascending Dose Trial of XEN-D0103
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
This study is an evaluation of the safety and tolerability of XEN-D0103 in healthy subjects.
Part 1 assesses the safety, tolerability and blood levels of the ascending single doses of
XEN-D0103. Blood levels of XEN-D0103 will be assessed when administered with food and also
without food in Part 2. The safety, tolerability and blood levels of XEN-D0103 will be
assessed following dosing for 10 days in Part 3.